The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Could Lipids Be a Key to Control Inflammation?

Could Lipids Be a Key to Control Inflammation?

March 18, 2011 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—Rheumatologists are well aware that patients with rheumatoid arthritis (RA) and other chronic inflammatory disorders are at an increased risk of developing cardiovascular disease. It has also been established that high-density lipoprotein (HDL) levels correlate inversely with cardiovascular risk. Recent research, such as the study by Carpintero et al, which was led by a team of Swiss, Italian, and Australian investigators, have begun to narrow in on HDL’s ability to interfere with T-cell binding to monocytes, inhibiting production of proinflammatory cytokines.1

You Might Also Like
  • Researchers Work to Untangle the Relationship Between Blood Lipids, Bone Health & Diet
  • Aggregated Neutrophils Limit Inflammation
  • Cholesterol Levels in Patients with RA Starting Methotrexate
Explore This Issue
March 2011
Also By This Author
  • Strides in Recognition and Management of Joint Hypermobility Syndrome

These discoveries have led to an important question: Might the intersection of cholesterol metabolism, atherogenesis, and inflammatory signaling offer a potential pathway for interventional strategies to combat inflammatory disease? These were the questions addressed by the research scientists who presented at the session, “A Critical Role for Lipid Metabolism in the Interplay between Atherosclerosis and Autoimmune Disorders.” [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Kerry-Anne Rye, PhD, a professor at the University of Sydney, Australia, addressed the question: “Is it possible to use HDL to attenuate arthritis?” She and her group have conducted experiments at the Heart Research Institute of Sydney, where she is associate director, aimed at exploring a possible use of HDL to counteract the inflammatory processes that result in joint erosion.

Dr. Rye prefaced her presentation of her group’s current work with a succinct description of HDLs. Although we commonly use one term to refer to high-density lipoproteins, she noted, they do not comprise a single entity. Rather, HDLs are a complex series of subpopulations of particles, all of which are continually being interconverted from one to another by a range of factors in the circulation. HDLs, she said, “start off as discoidal particles consisting of a phospholipid bilayer surrounded by apolipoproteins,” and are classified according to the presence of one or both of their main constituent apolipoproteins, apoA-1 and apoA-2.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Able to Alleviate Inflammation?

One of the antiatherogenic functions of HDL is its ability to efflux cholesterol, especially from macrophages in the artery walls. HDL also has antithrombotic, antiinflammatory, and antioxidant properties. There may be other beneficial properties of HDL which have yet to be identified, Dr. Rye said.

To investigate HDL’s possible antiinflammatory functions, Dr. Rye’s group used a female Lewis rat model of induced arthritis. The rats received a single intraperitoneal injection of PG-PS, a bacterial cell wall component consisting of peptidoglycan and polysaccharide chains that induces a systemic inflammatory response. All animals exhibited a biphasic inflammatory response after the injection of PG-PS. The acute phase was characterized by joint swelling (rated on a score of 0 to 5). After a brief remission period (Days Seven to Nine following injection), inflammation returned, and entered a chronic phase until Day 21, when the study ended.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Cardiovascular disease, cholesterol, high-density lipoprotein, inflammation, Lipid, Rheumatoid arthritisIssue: March 2011

You Might Also Like:
  • Researchers Work to Untangle the Relationship Between Blood Lipids, Bone Health & Diet
  • Aggregated Neutrophils Limit Inflammation
  • Cholesterol Levels in Patients with RA Starting Methotrexate
  • Cardiovascular Disease Risk High in RA Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.